ALE.C04

Alentis’ ALE.C04 receives fast track designation from FDA
Pharmaceutical Business Review
Fri, 08/25/23 - 09:44 am
Alentis Therapeutics
FDA
ALE.C04
metastatic head and neck squamous cell carcinoma
head and neck cancer